Gedatolisib von Celcuity zeigt überzeugende Ergebnisse in Phase-3-Studie zu Brustkrebs

Get more from THE OPTIONS BULLY on Patreon

Get more from THE OPTIONS BULLY on Patreon

Celcuity's gedatolisib shows 76% reduction in disease progression risk for HR+/HER2- breast cancer. Phase 3 trial achieved 9.3-month PFS vs 2.0 months. NDA submission starts September 2025.

This study systematically examines the influence of different gas-phase correction strategies on the computed thermodynamic landscape of nitrogen reduction reaction (NRR) over Mo2C(0001) MXene. By co....

Location: Birmingham or Coventry

Celcuity (Nasdaq: CELC), a clinical-stage biotechnology company focused on developing targeted oncology therapies, has announced the timing for its Q1 2025 financial results release. The company will release its results after market close on Wednesday, May 14, 2025, followed by a management-hosted webcast and conference call at 4:30 p.m. Eastern Time. Domestic participants can dial 1-800-717-1738, while international callers should use 1-646-307-1865. A live webcast will be available, and a replay will be accessible on Celcuity's website after the event.

This content is password protected. To view it please enter your password below: Password: ### _Related_ * * * ### Discover more from Overwise Trend trading Subscribe to get the latest posts sent to your email. Type your email… Subscribe

Phase 3 trial data expected Q2 2025 as Celcuity reports $235M cash position. Impressive 77-month survival data in breast cancer study. See full pipeline updates.